- Home
- MedBound Hub
- InternshipInternship
- BiographyBiography
- InterviewInterview
- Medicine
- Pharmacy
- Physical Therapy
- Biotechnology
- College/InstituteCollege/Institute
- Dentistry
- Blog
- Wellness & Nutrition
- Nursing
- Opinion
- Videos
Surgify Medical, a young Finnish MedTech startup, has secured €7 million Series A investment to catapult its best-selling bone surgery technology to the next level. The Espoo-founded startup is changing the way surgeons perform delicate procedures with its innovative Surgify Halo system.
The heavyweights turned out for the funding round, which was led by ZEISS Ventures with the European Innovation Council Fund also participating. Existing investors Lednil and Cascara Ventures participated in the milestone round.
Why this matters to surgeons and patients.
Traditional surgical drills are highly hazardous, rotating at tens of thousands of revolutions per minute. When such devices contact soft tissues such as nerves or blood vessels accidentally, the result may be disastrous for patients. Damage to soft tissues during bone surgery already costs healthcare systems more than €4 billion annually worldwide.
“ZEISS brings unparalleled experience in surgical technology and a global network, while the EIC’s continued support and earlier grant financing underscore the European innovation ecosystem’s confidence in our solution. With this funding and regulatory approvals in both the EU and the U.S., we are well-positioned to bring our unique technology to more surgeons and patients internationally,” said Visa Sippola, Co-founder and CEO of Surgify Medical
Surgify Halo solves this most significant obstacle by differentiating smartly between tough bone and delicate soft tissue. The tissue-selective technology allows for cuts to be made with unprecedented precision while greatly reducing the risk of accidental damage to sensitive structures.
Nordic success continues
Since its original launch in the Nordic territories, Surgify has already been used in more than 1,000 patient procedures with phenomenal results. The company is now set to accelerate expansion in the European Union and the United States, where leading hospitals are only just beginning to adopt this revolutionary technology.
“We are excited to partner with Surgify in their mission to establish a new benchmark for surgical safety. Surgify’s Halo burrs offer exceptional control at cutting rates comparable to traditional burrs, while simultaneously safeguarding delicate soft tissues. This makes the switch to Halo burrs an obvious choice for surgeons. We are eager to support the team as they expand their solution on a global scale,” explains Dr. Boris Hofmann, Head of ZEISS Ventures
Future Applications in Robotic Surgery
Beyond traditional applications, Surgify's technology offers great promise in being applied to robotic surgery. The system's ability to provide precision automated bone cutting can open up new fronts in surgical robotics that can change the way complex procedures are performed.
“Surgify’s technology is a major breakthrough in today’s evolving healthcare landscape. With over a thousand patient procedures, Surgify Halo has already left a significant footprint in the field. The company aims to protect patients, save costs, and has already achieved groundbreaking developments in robotic surgery applications,” said Alan Raffensperger, Chairman of Surgify Medical.
With a turnover of €14 million and offices in the United States, Sweden, Denmark, and Finland, Surgify Medical is well-placed to capture significant market share in the multi-billion euro bone surgery device market.
Reference:
EU Startup: Finnish MedTech startup Surgify Medical raises €7 million to make bone surgery safer with tissue-selective technology https://www.eu-startups.com/2025/05/finnish-medtech-startup-surgify-medical-raises-e7-million-to-make-bone-surgery-safer-with-tissue-selective-technology
(Input from various sources)
(Rehash/Muhammad Faisal Arshad/MSM)
